Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study
- PMID: 17265500
- DOI: 10.1002/art.22381
Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study
Abstract
Objective: To assess the prevalence, risk factors, and long-term outcome of uveitis in patients with juvenile idiopathic arthritis (JIA).
Methods: An inception cohort of all 1,081 patients diagnosed as having JIA at a single tertiary care center was established. A questionnaire and followup telephone calls were used to confirm the diagnosis of uveitis. Ophthalmologists' records of patients with uveitis were collected. Kaplan-Meier and Cox regression analyses were used to assess risk factors for developing uveitis and for complications of uveitis.
Results: After a mean followup time of 6.9 years, 142 of 1,081 patients (13.1%) had developed uveitis. Risk factors were young age at diagnosis, female sex, antinuclear antibody positivity, and the subtype of JIA. The relative contribution of these risk factors was different for the different subtypes of JIA. Until the end of the study, uveitis complications had developed in 53 of 142 patients with uveitis (37.3%; 4.9% of the total cohort). Only 16 of 175 involved eyes (9.1%) in 14 of 108 patients (13%; 1.3% of the total cohort) for whom ophthalmology reports were available had best corrected visual acuity less than 20/40 (mean followup time for uveitis of 6.3 years). Abnormal vision was associated with synechiae or cataract.
Conclusion: Risk factors for developing uveitis were different among subtypes of JIA. The long-term outcome of JIA-associated uveitis in our cohort was excellent despite the high rate of complications.
Similar articles
-
Risk factors and longterm outcome of juvenile idiopathic arthritis-associated uveitis in Switzerland.J Rheumatol. 2008 Apr;35(4):703-6. Epub 2008 Feb 15. J Rheumatol. 2008. PMID: 18278829
-
Extended oligoarthritis and other risk factors for developing JIA-associated uveitis under ILAR classification and its implication for current screening guideline.Ocul Immunol Inflamm. 2006 Dec;14(6):353-7. doi: 10.1080/09273940600977233. Ocul Immunol Inflamm. 2006. PMID: 17162606
-
Visual outcomes in children with juvenile idiopathic arthritis-associated uveitis.Ophthalmology. 2006 Oct;113(10):1874-7. doi: 10.1016/j.ophtha.2006.05.016. Epub 2006 Aug 1. Ophthalmology. 2006. PMID: 16884776
-
Treatment of juvenile idiopathic arthritis-associated uveitis: challenges and update.Curr Opin Rheumatol. 2011 Sep;23(5):432-6. doi: 10.1097/BOR.0b013e328349c324. Curr Opin Rheumatol. 2011. PMID: 21738033 Review.
-
Pediatric rheumatology for the adult rheumatologist II: uveitis in juvenile idiopathic arthritis.J Clin Rheumatol. 2007 Aug;13(4):205-10. doi: 10.1097/RHU.0b013e31813c0e36. J Clin Rheumatol. 2007. PMID: 17762455 Review.
Cited by
-
Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study.Ophthalmology. 2013 Jan;120(1):186-92. doi: 10.1016/j.ophtha.2012.07.052. Epub 2012 Oct 11. Ophthalmology. 2013. PMID: 23062650 Free PMC article.
-
Identification of novel autoantigens as potential biomarkers in juvenile idiopathic arthritis associated uveitis.Front Pediatr. 2023 Jan 9;10:1091308. doi: 10.3389/fped.2022.1091308. eCollection 2022. Front Pediatr. 2023. PMID: 36699287 Free PMC article.
-
Antinuclear antibodies (ANA) as a criterion for classification and diagnosis of systemic autoimmune diseases.J Transl Autoimmun. 2022 Jan 19;5:100145. doi: 10.1016/j.jtauto.2022.100145. eCollection 2022. J Transl Autoimmun. 2022. PMID: 35128372 Free PMC article.
-
Developing electronic health record algorithms that accurately identify patients with juvenile idiopathic arthritis.Semin Arthritis Rheum. 2023 Apr;59:152167. doi: 10.1016/j.semarthrit.2023.152167. Epub 2023 Jan 18. Semin Arthritis Rheum. 2023. PMID: 36708593 Free PMC article.
-
Ocular Involvement in Juvenile Idiopathic Arthritis: Classification and Treatment.Clin Rev Allergy Immunol. 2015 Dec;49(3):271-7. doi: 10.1007/s12016-014-8436-9. Clin Rev Allergy Immunol. 2015. PMID: 25081063 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical